Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b open-label single-arm study of venetoclax monotherapy in relapsed or refractory chronic lymphocytic leukemia
NL-OMON55465Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by AbbVie Inc. Primary endpoint: Complete remission rate. Started Mar 2017; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON55465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55465.